ATE157975T1 - Oxazolidinedione-derivate, ihre herstellung und ihre verwendung zur hemmung zucker und lipid in blut - Google Patents

Oxazolidinedione-derivate, ihre herstellung und ihre verwendung zur hemmung zucker und lipid in blut

Info

Publication number
ATE157975T1
ATE157975T1 AT94301341T AT94301341T ATE157975T1 AT E157975 T1 ATE157975 T1 AT E157975T1 AT 94301341 T AT94301341 T AT 94301341T AT 94301341 T AT94301341 T AT 94301341T AT E157975 T1 ATE157975 T1 AT E157975T1
Authority
AT
Austria
Prior art keywords
lipid
blood
preparation
combine
substituted
Prior art date
Application number
AT94301341T
Other languages
German (de)
English (en)
Inventor
Takashi Sohda
Hitoshi Ikeda
Yu Momose
Sachiko Imai
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE157975T1 publication Critical patent/ATE157975T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
AT94301341T 1993-02-26 1994-02-25 Oxazolidinedione-derivate, ihre herstellung und ihre verwendung zur hemmung zucker und lipid in blut ATE157975T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3823693 1993-02-26
JP19730493 1993-08-09

Publications (1)

Publication Number Publication Date
ATE157975T1 true ATE157975T1 (de) 1997-09-15

Family

ID=26377445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94301341T ATE157975T1 (de) 1993-02-26 1994-02-25 Oxazolidinedione-derivate, ihre herstellung und ihre verwendung zur hemmung zucker und lipid in blut

Country Status (18)

Country Link
US (4) US5665748A (OSRAM)
EP (1) EP0612743B1 (OSRAM)
JP (2) JP3328720B2 (OSRAM)
KR (1) KR940019699A (OSRAM)
CN (1) CN1098411A (OSRAM)
AT (1) ATE157975T1 (OSRAM)
AU (1) AU673034B2 (OSRAM)
CA (1) CA2116387C (OSRAM)
DE (1) DE69405425T2 (OSRAM)
DK (1) DK0612743T3 (OSRAM)
ES (1) ES2108375T3 (OSRAM)
FI (1) FI940904L (OSRAM)
GR (1) GR3025342T3 (OSRAM)
HU (1) HUT70159A (OSRAM)
NO (1) NO305079B1 (OSRAM)
PH (1) PH31468A (OSRAM)
RU (1) RU2126797C1 (OSRAM)
TW (1) TW268952B (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468762A (en) * 1994-05-18 1995-11-21 American Home Products Corporation Azolidinediones as antihyperglycemic agents
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
CA2171702A1 (en) * 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
JPH09136877A (ja) * 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
PT891340E (pt) 1996-04-03 2003-03-31 Takeda Chemical Industries Ltd Derivados de oxazol sua preparacao e utilizacao
JPH09323930A (ja) 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
FR2749583B1 (fr) 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
KR100579765B1 (ko) * 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
IL128600A0 (en) 1996-08-19 2000-01-31 Japan Tobacco Inc Propionic acid derivatives and pharmaceutical compositions containing them
US6011036A (en) * 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CN1053186C (zh) * 1998-07-09 2000-06-07 华东理工大学 喹啉噁唑啉化合物
JP2000044551A (ja) * 1998-07-27 2000-02-15 Konica Corp ３−置換−３−オキソ−２−（２，４−オキサゾリジンジオン−３−イル）プロピオン酸アミド化合物の製造方法
WO2000018745A1 (en) * 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Oxazolidine derivatives for the treatment and prevention of metabolic bone disorders
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
EP1135127B1 (en) * 1998-12-01 2006-01-25 Dr. Reddy's Research Foundation New pharmaceutical composition and the process for its preparation
HUP0200996A3 (en) 1999-04-07 2003-01-28 Sankyo Company Ltd Chuo Ku Amine derivatives, pharmaceutical compositions containing them and their use
EP1194147B1 (en) 1999-06-18 2007-01-10 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
ES2265952T3 (es) 1999-06-18 2007-03-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y ariloxazolidindiona.
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP4316787B2 (ja) * 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
US7105551B2 (en) 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
EP1394154A4 (en) * 2001-03-23 2005-05-18 Takeda Pharmaceutical FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE
TW200300681A (en) * 2001-11-12 2003-06-16 Ono Pharmaceutical Co Carboxylic acid derivative compound and medicament containing same as active ingredient
AU2003203170A1 (en) * 2002-01-17 2003-07-30 Takeda Chemical Industries, Ltd. Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
TWI327462B (en) * 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
AU2004236173B2 (en) 2003-04-30 2008-07-03 The Institutes For Pharmaceutical Discovery, Llc Substituted carboxylic acids
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
BRPI0506919A (pt) * 2004-01-20 2007-06-05 Merck & Co Inc composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal deste farmaceuticamente aceitável
JP2008518926A (ja) * 2004-10-28 2008-06-05 ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー 置換フェニルアルカン酸
TW200932219A (en) * 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4430337A (en) * 1982-06-23 1984-02-07 Pfizer Inc. Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5143930A (en) * 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
JP2991801B2 (ja) * 1990-04-27 1999-12-20 三共株式会社 ベンジリデンチアゾリジン化合物
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
KR100249988B1 (ko) * 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
KR100204938B1 (ko) * 1991-07-30 1999-06-15 오노다 마사요시 비스헤테로사이클릭 유도체 또는 이의 염, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
EP0605729B1 (en) * 1992-04-30 2000-07-26 Taiho Pharmaceutical Co., Ltd. Oxazolidine derivative and pharmaceutically acceptable salt thereof
US5928152A (en) * 1994-08-05 1999-07-27 Acuson Corporation Method and apparatus for a baseband processor of a receive beamformer system

Also Published As

Publication number Publication date
JP2000191651A (ja) 2000-07-11
EP0612743B1 (en) 1997-09-10
DK0612743T3 (da) 1998-04-20
DE69405425D1 (de) 1997-10-16
NO305079B1 (no) 1999-03-29
KR940019699A (ko) 1994-09-14
GR3025342T3 (en) 1998-02-27
FI940904A7 (fi) 1994-11-29
PH31468A (en) 1998-11-03
HU9400578D0 (en) 1994-05-30
AU5515894A (en) 1994-09-01
US6147099A (en) 2000-11-14
FI940904A0 (fi) 1994-02-25
CA2116387A1 (en) 1994-08-27
EP0612743A1 (en) 1994-08-31
US6552058B1 (en) 2003-04-22
ES2108375T3 (es) 1997-12-16
US5665748A (en) 1997-09-09
AU673034B2 (en) 1996-10-24
DE69405425T2 (de) 1998-03-19
NO940610L (no) 1994-08-29
HUT70159A (en) 1995-09-28
JPH07165735A (ja) 1995-06-27
US5972970A (en) 1999-10-26
FI940904L (fi) 1994-11-29
CA2116387C (en) 2003-12-23
TW268952B (OSRAM) 1996-01-21
NO940610D0 (no) 1994-02-23
CN1098411A (zh) 1995-02-08
RU2126797C1 (ru) 1999-02-27
JP3328720B2 (ja) 2002-09-30

Similar Documents

Publication Publication Date Title
DE69405425D1 (de) Oxazolidinedione-Derivate, ihre Herstellung und ihre Verwendung zur Hemmung Zucker und Lipid in Blut
DE68920654D1 (de) 4-Oxochinolin-3-carbonsäure-Derivate, ihre Herstellung und ihre Verwendung.
RU94006013A (ru) Производные оксазолидиндиона, их получение и применение
NO173867C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzamider
FI925871A0 (fi) Menetelmä terapeuttisesti aktiivisten fenyyliguanidiinijohdannaisten valmistamiseksi
DE3677471D1 (de) Pyrrolidinylamidesterderivate mit antiprolylendopeptidaseaktivitaet, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen.
DE69432542D1 (de) Tetraderivate, ihre Herstellung und Verwendung
AU3381389A (en) Derivative of caffeic acid and pharmaceutical composition containing the same
ES2065994T3 (es) Beta-dicetonas substituidas.
FI881104A0 (fi) Menetelmä antidiabeettisina aineina käytettävien bentsoksatsiinijohdannaisten valmistamiseksi
EP0347942A3 (en) Ferroelectric chiral smectic liquid crystal composition and liquid crystal device using same
ATE102925T1 (de) Optisch aktive 2,5-diphenylpyridine.
AU3624089A (en) Analgesic phenothiazine derivatives
ATE110763T1 (de) Ferroelektrische chirale smektische flüssigkristallzusammensetzung und dieselbe verwendende vorrichtung.
EP0410305A3 (en) Use of bis(4-hydroxyphenylthio) methane derivatives in treating diabetes mellitus
DE68918358D1 (de) Ferroelektrische chirale smektische Flüssigkristallzusammensetzung und Vorrichtung mit dieser Zusammensetzung.
EP0350936A3 (en) Ferroelectric chiral smectic liquid crystal composition and liquid crystal device using same
ES2112470T3 (es) Derivados de piridazinona, procedimientos de produccion y utilizacion.
ATE143591T1 (de) Verwendung von bis-(p- hydroxyphenylthio)methanderivaten zur hemmung der fortschreitenden entwicklung von insulinabhängingem diabetes mellitus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee